Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.
Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise's performance and other pipeline updates, when Gilead (GILD) reports second-quarter 2019 results.
Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.
Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.
Will Strong Jakafi Sales Drive Incyte (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will primarily focus on Jakafi sales and pipeline updates, when Incyte (INCY) reports second-quarter 2019 results.
5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2
by Zacks Equity Research
We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.
Acorda (ACOR) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Acorda's (ACOR) second-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.
What's in the Cards for AcelRx (ACRX) This Earnings Season?
by Zacks Equity Research
AcelRx (ACRX) will provide updates on the launch and sales of Dsuvia when it releases second-quarter 2019 results.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $66.64, marking a +0.36% move from the previous day.
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
by Zacks Equity Research
Key highlights of the past week include earnings update, collaborations and other pipeline news.
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Is a Beat in Store for Repligen (RGEN) This Earnings Season?
by Zacks Equity Research
On Repligen's (RGEN) second-quarter earnings call, investor focus will be on its advancement with the proposed acquisition of C Technologies, Inc.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMAG (AMAG) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect AMAG (AMAG) to provide updates on its revenue-driving products, when it reports second-quarter earnings.
What's in Store for Anika Therapeutics' (ANIK) Q2 Earnings?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) second-quarter earnings call, investor focus will be on its progress with the U.S. approval of its orthopedic product Cingal.
Q2 Earnings Surprise in the Cards, Healthcare ETFs to Buy
by Sweta Killa
With earnings surprise in cards, the healthcare sector is expected to witness earnings growth of 1.7% in the second quarter, suggesting continued outperformance for healthcare ETFs.
Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $66.92 in the latest trading session, marking a -0.03% move from the prior day.
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
by Zacks Equity Research
Key highlights of the past week include collaborations and other pipeline updates.
Company News for Jul 16, 2019
by Zacks Equity Research
Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT
Gilead-Galapagos Ink $5.1B Deal for Additional Compounds
by Zacks Equity Research
Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.
Trump Drops Drug Rebate Proposal: What's Next and What Stocks to Play
by Christopher Vargas
The Trump administration announced Thursday that it's deciding to withdraw its proposal to eliminate rebates from government drug plans.